Therapeutic potential of CDK11 in cancer
Open Access
- 28 February 2023
- journal article
- editorial
- Published by Wiley in Clinical and Translational Medicine
- Vol. 13 (3) , e1201
Abstract
Human cyclin‐dependent kinases (CDKs) direct the progression of the cell cycle and transcription. They are deregulated in tumours, and despite their involvement in the regulation of basic cellular processes, many CDKs are promising targets for cancer therapy. CDK11 is an essential gene for the growth of many malignancies; however, its primary cellular function has been obscure, and the mode‐of‐action of OTS964, the first CDK11 inhibitor and antiproliferative compound, has been unknown. A recent study has shown that OTS964 prevents spliceosome activation, revealing a key role of CDK11 in the regulation of pre‐mRNA splicing. In light of these findings, we discuss the therapeutic potential of CDK11 in cancer.Keywords
This publication has 12 references indexed in Scilit:
- Pharmacologic modulation of RNA splicing enhances anti-tumor immunityCell, 2021
- Efficient RNA polymerase II pause release requires U2 snRNP functionMolecular Cell, 2021
- Roles of CDK/Cyclin complexes in transcription and pre-mRNA splicing: Cyclins L and CDK11 at the cross-roads of cell cycle and regulation of gene expressionSeminars in Cell & Developmental Biology, 2020
- Dissecting the Pol II transcription cycle and derailing cancer with CDK inhibitorsNature Chemical Biology, 2020
- RNA Splicing by the SpliceosomeAnnual Review of Biochemistry, 2020
- CDK11 is required for transcription of replication-dependent histone genesNature Structural & Molecular Biology, 2020
- Transcription-Associated Cyclin-Dependent Kinases as Targets and Biomarkers for Cancer TherapyCancer Discovery, 2020
- Off-target toxicity is a common mechanism of action of cancer drugs undergoing clinical trialsScience Translational Medicine, 2019
- The emerging roles and therapeutic potential of cyclin-dependent kinase 11 (CDK11) in human cancerOncotarget, 2016
- The spliceosome is a therapeutic vulnerability in MYC-driven cancerNature, 2015